Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | FABP2 | P12104 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380153 | 1.00 | PTGS1 (0.56) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL2722631 | 1.00 | PTGS1 (0.56) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL5605512 | 0.98 | PTGS1 (0.56) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| Hydrochloric Acid SCHEMBL7143180 | 0.90 | PTGS1 (0.48) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL12103285 | 0.89 | PTGS1 (0.53) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL16193387 | 0.87 | LMNA (0.64) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL15367915 | 0.85 | PTGS2 (0.64) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL5140144 | 0.85 | PTGS1 (0.45) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| Flurbiprofen SCHEMBL7581730 | 0.85 | AKR1C3 (0.52) | PTGS1PTGS2MEN1KMT2AAKR1C3 | |
| SCHEMBL29198052 | 0.84 | PTGS2 (0.66) | PTGS1PTGS2MEN1KMT2AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | claimed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | claimed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | claimed |
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2010-12-16 | — | — | US | claimed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | claimed |
| EP-1526839-B1 | ORAL PHARMACEUTICAL FORMS OF LIQUID DRUGS HAVING IMPROVED BIOAVAILABILITY | NICOX SA (FR) | 2007-03-14 | — | — | EP | claimed |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | NICOX S.A. (FR) | 2006-08-03 | — | — | US | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| WO-2017080989-A1 | (R)-FLURIPROFEN FOR THE PREVENTION AND/OR TREATMENT OF DIABETES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2017-05-18 | — | — | WO | disclosed |
| US-8802726-B2 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2014-08-12 | — | — | US | disclosed |
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002053188-A1 | COMPOSITIONS COMPRISING CYCLODEXTRINS AND NO-RELEASING DRUGS | NICOX S.A. (FR) | 2002-07-11 | — | — | WO | disclosed |
| EP-1219306-A1 | Compositions comprising cyclodextrins and NO- releasing drugs | NICOX S.A. (FR) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317630-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GRIK5, HRH2 | PTGS1 628/4885PTGS2 575/4885MEN1 771/4885 |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | PTGS1 811/4885PTGS2 940/4885MEN1 754/4885 |
| US-20060171969-A1 | Oral pharmaceutical forms of liquid drugs having improved bioavailability | ABCG2, SLCO1B1, SLCO4C1 | PTGS1 515/4885PTGS2 653/4885MEN1 2832/4885 |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | PTGS1 619/4885PTGS2 555/4885MEN1 907/4885 |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | PTGS1 1207/4885PTGS2 1659/4885MEN1 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.